C Albany1, N Adra2, A C Snavely3, C Cary4, T A Masterson4, R S Foster4, K Kesler5, T M Ulbright6, L Cheng6, M Chovanec7, F Taza2, K Ku8, M J Brames2, N H Hanna2, L H Einhorn2. 1. Division of Hematology & Medical Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, USA. Electronic address: calbany@iu.edu. 2. Division of Hematology & Medical Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, USA. 3. PDstat, Chapel Hill, Indiana University School of Medicine, Indianapolis, USA. 4. Department of Urology, Indiana University School of Medicine, Indianapolis, USA. 5. Thoracic Division, Department of Surgery, Indiana University School of Medicine, Indianapolis, USA. 6. Department of Pathology & Laboratory Medicine, Indiana University School of Medicine, Indianapolis, USA. 7. Division of Hematology & Medical Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, USA; 2nd Department of Oncology, Faculty of Medicine, Comenius University, Bratislava, USA; National Cancer Institute, Bratislava, Slovakia, USA. 8. Division of Hematology & Medical Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, USA; Division of Hematology & Medical Oncology, University of Wisconsin School of Medicine and Public Health, Madison, USA.
Abstract
Background: To report our experience utilizing a multidisciplinary clinic (MDC) at Indiana University (IU) since the publication of the International Germ Cell Cancer Collaborative Group (IGCCCG), and to compare our overall survival (OS) to that of the National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) Program. Patients and methods: We conducted a retrospective analysis of all patients with metastatic germ-cell tumor (GCT) seen at IU from 1998 to 2014. A total of 1611 consecutive patients were identified, of whom 704 patients received an initial evaluation by our MDC (including medical oncology, pathology, urology and thoracic surgery) and started first-line chemotherapy at IU. These 704 patients were eligible for analysis. All patients in this cohort were treated with cisplatin-etoposide-based combination chemotherapy. We compared the progression-free survival (PFS) and OS of patients treated at IU with that of the published IGCCCG cohort. OS of the IU testis cancer primary cohort (n = 622) was further compared with the SEER data of 1283 patients labeled with 'distant' disease. The Kaplan-Meier method was used to estimate PFS and OS. Results: With a median follow-up of 4.4 years, patients with good, intermediate, and poor risk disease by IGCCCG criteria treated at IU had 5-year PFS of 90%, 84%, and 54% and 5-year OS of 97%, 92%, and 73%, respectively. The 5-year PFS for all patients in the IU cohort was 79% [95% confidence interval (CI) 76% to 82%]. The 5-year OS for the IU cohort was 90% (95% CI 87% to 92%). IU testis cohort had 5-year OS 94% (95% CI 91% to 96%) versus 75% (95% CI 73% to 78%) for the SEER 'distant' cohort between 2000 and 2014, P-value <0.0001. Conclusion: The MDC approach to GCT at high-volume cancer center associated with improved OS outcomes in this contemporary dataset. OS is significantly higher in the IU cohort compared with the IGCCCG and SEER 'distant' cohort.
Background: To report our experience utilizing a multidisciplinary clinic (MDC) at Indiana University (IU) since the publication of the International Germ Cell Cancer Collaborative Group (IGCCCG), and to compare our overall survival (OS) to that of the National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) Program. Patients and methods: We conducted a retrospective analysis of all patients with metastatic germ-cell tumor (GCT) seen at IU from 1998 to 2014. A total of 1611 consecutive patients were identified, of whom 704 patients received an initial evaluation by our MDC (including medical oncology, pathology, urology and thoracic surgery) and started first-line chemotherapy at IU. These 704 patients were eligible for analysis. All patients in this cohort were treated with cisplatin-etoposide-based combination chemotherapy. We compared the progression-free survival (PFS) and OS of patients treated at IU with that of the published IGCCCG cohort. OS of the IU testis cancer primary cohort (n = 622) was further compared with the SEER data of 1283 patients labeled with 'distant' disease. The Kaplan-Meier method was used to estimate PFS and OS. Results: With a median follow-up of 4.4 years, patients with good, intermediate, and poor risk disease by IGCCCG criteria treated at IU had 5-year PFS of 90%, 84%, and 54% and 5-year OS of 97%, 92%, and 73%, respectively. The 5-year PFS for all patients in the IU cohort was 79% [95% confidence interval (CI) 76% to 82%]. The 5-year OS for the IU cohort was 90% (95% CI 87% to 92%). IU testis cohort had 5-year OS 94% (95% CI 91% to 96%) versus 75% (95% CI 73% to 78%) for the SEER 'distant' cohort between 2000 and 2014, P-value <0.0001. Conclusion: The MDC approach to GCT at high-volume cancer center associated with improved OS outcomes in this contemporary dataset. OS is significantly higher in the IU cohort compared with the IGCCCG and SEER 'distant' cohort.
Authors: Timothy D Gilligan; Jerome Seidenfeld; Ethan M Basch; Lawrence H Einhorn; Timothy Fancher; David C Smith; Andrew J Stephenson; David J Vaughn; Roxanne Cosby; Daniel F Hayes Journal: J Clin Oncol Date: 2010-06-07 Impact factor: 44.544
Authors: G Varuni Kondagunta; Jennifer Bacik; Alessia Donadio; Dean Bajorin; Stephanie Marion; Joel Sheinfeld; George J Bosl; Robert J Motzer Journal: J Clin Oncol Date: 2005-09-20 Impact factor: 44.544
Authors: R de Wit; J T Roberts; P M Wilkinson; P H de Mulder; G M Mead; S D Fosså; P Cook; L de Prijck; S Stenning; L Collette Journal: J Clin Oncol Date: 2001-03-15 Impact factor: 44.544
Authors: Darren R Feldman; Joel Sheinfeld; Dean F Bajorin; Patricia Fischer; Stefan Turkula; Nicole Ishill; Sujata Patil; Manjit Bains; Lilian M Reich; George J Bosl; Robert J Motzer Journal: J Clin Oncol Date: 2010-03-01 Impact factor: 44.544
Authors: Madhur Nayan; Michael A S Jewett; Lynn Anson-Cartwright; Philippe L Bedard; Malcolm Moore; Peter Chung; Padraig Warde; Joan Sweet; Martin O'Malley; Robert J Hamilton Journal: Can Urol Assoc J Date: 2016 May-Jun Impact factor: 1.862
Authors: Elio Mazzone; Sophie Knipper; Francesco A Mistretta; Zhe Tian; Carlotta Palumbo; Denis Soulieres; Ottavio De Cobelli; Francesco Montorsi; Shahrokh F Shariat; Fred Saad; Alberto Briganti; Pierre I Karakiewicz Journal: World J Urol Date: 2019-08-28 Impact factor: 4.226
Authors: Sabine Kliesch; Stefanie Schmidt; Doris Wilborn; Clemens Aigner; Walter Albrecht; Jens Bedke; Matthias Beintker; Dirk Beyersdorff; Carsten Bokemeyer; Jonas Busch; Johannes Classen; Maike de Wit; Klaus-Peter Dieckmann; Thorsten Diemer; Anette Dieing; Matthias Gockel; Bernt Göckel-Beining; Oliver W Hakenberg; Axel Heidenreich; Julia Heinzelbecker; Kathleen Herkommer; Thomas Hermanns; Sascha Kaufmann; Marko Kornmann; Jörg Kotzerke; Susanne Krege; Glen Kristiansen; Anja Lorch; Arndt-Christian Müller; Karin Oechsle; Timur Ohloff; Christoph Oing; Ulrich Otto; David Pfister; Renate Pichler; Heinrich Recken; Oliver Rick; Yvonne Rudolph; Christian Ruf; Joachim Schirren; Hans Schmelz; Heinz Schmidberger; Mark Schrader; Stefan Schweyer; Stefanie Seeling; Rainer Souchon; Christian Winter; Christian Wittekind; Friedemann Zengerling; Dirk-Henrik Zermann; Roger Zillmann; Peter Albers Journal: Urol Int Date: 2021-01-07 Impact factor: 2.089
Authors: Fadi Taza; Michal Chovanec; Anna Snavely; Nasser H Hanna; Clint Cary; Timothy A Masterson; Richard S Foster; Lawrence H Einhorn; Costantine Albany; Nabil Adra Journal: J Clin Oncol Date: 2020-03-05 Impact factor: 44.544
Authors: Raul Caso; Gregory D Jones; Kay See Tan; George J Bosl; Samuel A Funt; Joel Sheinfeld; Victor E Reuter; David Amar; Gregory Fischer; Daniela Molena; Gaetano Rocco; Manjit S Bains; Darren R Feldman; David R Jones Journal: Ann Thorac Surg Date: 2020-08-31 Impact factor: 4.330